title: Suramin inhibits the growth of nasopharyngeal carcinoma cells via the             downregulation of osteopontin.
abstract: Radiotherapy is the principal therapy for nasopharyngeal carcinoma (NPC)             at early stages. A number of chemotherapeutic methods have been used to inhibit             the progression of NPC at elevated stages. Suramin has been reported to inhibit             the growth of certain tumor cells via various pathways. In the present study,             we aimed to analyze the effects of suramin on the proliferation of NPC cells (CNE-2).             Suramin was proved to demonstrate NPC cell growth-inhibiting effects both in a             dose- and time-dependent manner. To determine the potential mechanisms of these             effects, western blotting and flow cytometric analysis were performed. Suramin             was found to have the potential to induce cell cycle arrest in S-phase CNE-2 cells.             Additionally, we found that the OPN level may decrease in suramin-treated CNE-2             cells. The changes of certain apoptosis- and p-AKT-associated proteins possibly             regulating the OPN expression were measured by western blotting. In conclusion,             suramin may function as a potential agent for the adjunctive therapy of NPC.
authors.affiliation: Department of Oncology, The First Affiliated Hospital, Chongqing                     Medical University, Chongqing 400016, P.R. China.
authors.forename: Shan
authors.initials: S
authors.lastname: Jiang
authors.forename: Xiaopin
authors.initials: X
authors.lastname: Chen
authors.forename: Chunyan
authors.initials: C
authors.lastname: Li
authors.forename: Xingping
authors.initials: X
authors.lastname: Zhang
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Yujuan
authors.initials: Y
authors.lastname: Yue
authors.forename: Guang
authors.initials: G
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma; D045744:Cell Line, Tumor; D015536:Down-Regulation / Q000187:drug effects*; D006801:Humans; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000378:metabolism / Q000473:pathology; D053495:Osteopontin / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D059807:S Phase Cell Cycle Checkpoints / Q000187:drug effects; D013498:Suramin / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D053495:Osteopontin; D013498:Suramin; D051057:Proto-Oncogene Proteins c-akt